| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | BMS-536924 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.16 | 0.002 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | 0.15 | 0.002 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.15 | 0.002 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |